Alnylam Landing Page

JWCA has advised alnylam on capital market transactions with nearly $1.7 billion in transaction value

September 2025: JWCA advises Alnylam Pharmaceuticals on its upsized $661 million convertible and capped call transaction to retire a portion of its outstanding convertible notes

September 2022: JWCA advises Alnylam Pharmaceuticals on its inaugural $1,035 million convertible and capped call transaction